agilon health, inc. revised revenue guidance for the full year ending December 31, 2024. For the full year, the company now expects total revenues of $6,350 million to $6,465 million compared to previous guidance of $6,350 million to $6,420 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +0.96% | +3.45% | -49.80% |
May. 30 | Baird Starts agilon health With Neutral Rating, $6 Price Target | MT |
May. 24 | Truist Lifts Price Target on agilon health to $6.50 From $6.40, Maintains Hold Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.80% | 2.59B | |
-23.90% | 2.81B | |
-22.24% | 2.63B | |
-2.11% | 217M | |
-44.86% | 180M | |
-32.40% | 115M |
- Stock Market
- Equities
- AGL Stock
- News agilon health, inc.
- Agilon health, inc. Revises Revenue Guidance for the Full Year Ending December 31, 2024